ADELAIDE, Australia / RankWire.AI / – Leading medical researchers in Australia have pinpointed a molecular switch that influences the dissemination of aggressive tumors, opening new avenues for therapy to prevent secondary cancers. In the study published in EMBO Molecular Medicine, scientists from Adelaide University and the Olivia Newton-John Cancer Research Institute showed that restoring the regulatory molecule miR-342 dramatically diminishes tumor metastasis. These results highlight a promising new approach to address triple-negative breast cancer by targeting dormant cancer cells before they develop into life-threatening lesions in distant organs.
Although triple-negative breast cancer represents 10% to 15% of the approximately 21,000 breast cancer diagnoses made annually in Australia, it accounts for a disproportionate share of mortality. This subtype is characterized by the absence of estrogen, progesterone, and HER2 receptors, which renders conventional hormone-targeted treatments ineffective. The lead researchers demonstrated that a decline in miR-342 levels activates a cancer-promoting pathway called E2F, enabling dormant cancer cells to metastasize and form dangerous secondary tumors throughout the body.
Targeted Interventions Present New Opportunities to Prevent High-Risk Metastasis
Using pre-clinical models, scientists found that boosting miR-342 levels significantly limited the spread of cancer to distant sites. Additionally, they identified that palbociclib, an already approved CDK4/6 inhibitor used for hormone receptor-positive breast cancers, was effective in halting metastatic growth in models with low miR-342 expression. These insights suggest that assessing miR-342 levels could enable clinicians to repurpose existing drugs for treating patients at high risk of metastasis.
Associate Professor Philip Gregory, co-senior author from Adelaide University’s Centre for Cancer Biology, confirmed that the biggest hurdle remains preventing metastasis. Gregory noted that because palbociclib targets the overactive E2F pathway, giving the medication after cancer cells have spread can prevent microscopic deposits from enlarging. Instead of solely focusing on shrinking primary tumors, this approach aims to stop microscopic secondary cancers from developing into life-threatening stages.
Peer-Reviewed Pre-Clinical Results Published in EMBO Molecular Medicine
The research team pointed out that the biological complexity of triple-negative breast cancer has historically posed challenges to developing universal targeted therapies. By identifying a specific biological vulnerability shared within a patient subgroup, this research paves the way for more personalized treatment strategies. As Australian scientists continue to explore a promising new method to combat triple-negative breast cancer, efforts are underway to validate these findings through patient-derived models ahead of clinical trials.
Medical oncologists and cancer research institutions across Australia have expressed enthusiasm, emphasizing the urgent need for expanding treatment options when first-line therapies fail. The research team intends to work with international clinical networks to expedite biomarker screening processes. Confirming the utility of miR-342 testing could soon allow physicians to identify suitable candidates for targeted CDK4/6 inhibitor treatments during early disease stages.